Le Lézard
Classified in: Health, Science and technology
Subject: PDT

Livongo Announces First Cellular-Enabled Blood Pressure Monitoring System in U.S.


MOUNTAIN VIEW, Calif., Sept. 17, 2018 /PRNewswire/ -- Livongo Health, the leading consumer digital health company empowering people with chronic conditions to live better and healthier lives, today announced the first cellular-enabled blood pressure monitoring system in the U.S. at Health 2.0. Cellular connectivity allows for easy checking and reporting from home, eliminating the so-called 'White Coat' syndrome that leads to unnecessary prescriptions for high blood pressure, and it also enables real-time insights and Health NudgesTM delivered when it is most effective. Nearly 65 percent of people already using Livongo for Diabetes also have hypertension, so an integrated approach makes it easier for members who are managing multiple conditions to stay healthy. Early results from some of Livongo's most innovative self-insured employers have shown meaningful health improvements for people with hypertension1.

Livongo Health (PRNewsfoto/Livongo Health)

The cellular-enabled monitoring system allows blood pressure data to transfer seamlessly from 'Cuff to Cloud'TM. Members receive personalized, insight-driven messaging (insights and Health NudgesTM) based on blood pressure data and trends. Members are also supported in real-time through digital alerts and virtual coaching from a team of licensed professionals certified in chronic-condition management.

"Just as we did with diabetes, Livongo wants to make it easier for people to stay healthy by checking their blood pressure, receiving real-time personalized feedback, sharing the information with their physician and other members of their connected care community from home, thereby avoiding a rise in blood pressure that can come with visiting a doctor," said Amar Kendale, Chief Product Officer, Livongo. "We're proud to introduce the first cellular-enabled blood pressure monitoring system to market in the U.S. and to add this capability to our comprehensive platform for people with all kinds of chronic conditions. This allows us to treat the whole person and the challenges they face in a seamless manner." 

Eighty-one percent of people in the initial cohort, who have both diabetes and hypertension, reduced their blood pressure. Individuals with mean blood pressures greater than 130/80 decreased their systolic blood pressure by nine mmHg on average1 lowering their risk of stroke and heart attacks by at least 35% and 25%, respectively2. In addition to strong clinical results, participants really liked the product, measured by a net promoter score of +76. Many of the early adopters of the solution also reported high adoption, with rates of 60 percent of eligible members enrolling in the program in the first 30 days1.

"As the first organization with an integrated offering that is delivering both clinical and financial results in the marketplace, Livongo is leading the way in empowering people to manage multiple chronic conditions," said Glen Tullman, Chief Executive Officer of Livongo. "Our early results show that by addressing the health of the whole person with a personalized approach and a seamless experience, we are making a difference in the lives of people who need it most."

After introducing a combined Hypertension and Diabetes solution in January 2018, the organization has rapidly expanded its footprint through the launch of new clients on the Hypertension product. Harris Health System, a large public healthcare provider in Texas, is among the many new clients who recognized the importance of having a single solution to address some of the most expensive chronic conditions affecting its workforce.  

Trina McCloskey is one among many people who have both conditions and who have been helped by Livongo's comprehensive platform. Using Livongo, she lowered her A1c from 13.0 to 6.0, reduced her blood pressure medication, and lost 40 pounds.

"I suffered three heart attacks at age 49 and knew I needed to make significant changes to my health," McCloskey said. "Joining Livongo and having my results in a single place makes it easier to manage my health and easily share information with my doctor. I also value the personal support from my health coach and find that it helps me make better choices every day to become healthier."

Diabetes and hypertension are the fastest growing and most expensive chronic conditions in the United States2, accounting for 458 billion dollars in healthcare costs3,4. By improving blood pressure control, through lifestyle changes, such as nutrition and exercise, and optimizing medications, people can reduce the chance of cardiovascular disease by 50 percent4. Cardiovascular care is the most important factor in avoiding long-term, expensive complications of diabetes5.

Amar Kendale, Livongo's Chief Product Officer, will take the stage today at Health 2.0 to provide the first Livongo for Hypertension demo. Glen Tullman, Livongo's Chief Executive Officer, will sit down with Health 2.0's Matthew Holt for a broad-ranging main stage conversation on health, healthcare, Livongo's growth and new products, and the Company's focus on the health of the whole person.

About Livongo Health
Livongo empowers people with chronic conditions to live better and healthier lives. We make it easier for people to stay healthy, starting with our diabetes prevention, and diabetes and hypertension offerings, by driving behavior change through the combination of consumer health technology, personalized recommendations, and real-time support at the point of impact. Powered by advanced data science, we create personalized experiences for our members, so they receive the right information, tools, and support, at the right time. Our approach is leading to better clinical6 and financial outcomes7 while creating a better experience for people with chronic conditions and their care team of family, friends, and medical professionals.

Livongo signature offerings include Livongo for Diabetes, Livongo for Hypertension, and Livongo Diabetes Prevention Program (DPP), powered by Retrofit. Livongo's objective is to serve the whole person, addressing each of their chronic conditions on a single platform, creating a truly seamless experience. Using reinforcement learning, Livongo can understand the personal health narrative of each member and offer real-time recommendations that are tailored to each person's unique health experience. For more information, visit: www.livongo.com.

References

  1. Livongo database internal analysis of members
  2. N Engl J Med 2015; 373:2103-2116
  3. The Cost of Diabetes, American Diabetes Association, 2018.
  4. Statistics About Diabetes, American Diabetes Association, 2018.
  5. Schutta, M. H. (2007), Diabetes and Hypertension: Epidemiology of the Relationship and Pathophysiology of Factors Associated With These Comorbid Conditions. Journal of the Cardiometabolic Syndrome, 2: 124?130. doi:10.1111/j.1559-4564.2007.06368.x
  6. Downing J, Bollyky J, Schneider J. Use of a Connected Glucose Meter and Certified Diabetes Educator Coaching to Decrease the Likelihood of Abnormal Blood Glucose Excursions: The Livongo for Diabetes Program. J Med Internet Res 2017;19(7):e234, DOI: 10.2196/jmir.6659
  7. Presentation at the 77th Annual American Diabetes Association's Scientific Sessions

 

SOURCE Livongo Health


These press releases may also interest you

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...

18 avr 2024
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: